Patient information centre
+ 44 20 38 684 002
info@virotherapy.eu



Post-registration experience

Publication on long-term treatment of patients, suffering from rare types of cancer, with oncolytic ECHO-7 virus reveals surprisingly positive results
The medical journal APMIS, (Acta Pathologica, Microbilogica Et Immunologica Scandinavia) has published clinical cases from Latvia when, thanks to the available virotherapy, patients suffering from cancer in the last stage have considerably exceeded life expectancy that is characteristic for such diagnoses. Publication elaborates on successful oncolytic virotherapy for patients suffering from histiocitary sarcoma in stage 4, small-cell lung cancer in stage 3 and melanoma in stage 4. Patients have received virotherapy for a long term and during the treatment their health condition and life quality have considerably improved. Patients undergoing virotherapy treatment were diagnosed 6.6, 3.5 and 7 years ago and their condition improved and remained stable during the treatment. These cancer patients received certain type of therapy, which was commenced 1 to 2 months after the diagnosis. These results are promising and allow believing that a long-term virotherapy with medicinal product invented in Latvia is effective in treating sarcoma, melanoma and small-cell lung cancer.

Immunotherapy with adapted virus (oncolytic virotherapy) extends survival of melanoma patients after a surgical removal of a tumour, retrospective study shows
The results of the retrospective study on oncolytic virotherapy efficiency have been published in medical journal Melanoma Research online version dated 15 July 2015.
http://journals.lww.com/melanomaresearch/

The study reveals that the stage IB-IIC melanoma patients treated with virotherapy were 4 to 6 times more likely to survive than those who, following the current guidelines for the treatment of melanoma, received no therapy and were observed only. It has been proved that Riga virus has an excellent safety profile, because no information has been received regarding any adverse side effects when undergoing virotherapy treatment or afterwards. Results show that the oncolytic virotherapy is a considerable gain for many patients, because it prolongs survival.
Source: Melanoma Research. 2015 Jul 24. Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A.

Progression-free period in II stage melanoma patients
Retrospective study, published in "Latvijas Ārsts" (Latvian Doctor), looked at progression-free period for stage II melanoma patients. Results showed that the observed patients had 6.7 times larger likelihood of disease return than those treated with oncolytic virotherapy.
Source: Latvijas Ārsts. 2012, No.5. Doniņa et al.


← Go back



 More →




Address
Teatra 9-9, Riga,
LV-1050, Latvia

Phone
+ 44 20 38 684 002 (UK, London)
+ 1 646 88 33 419 (USA, New York)
+ 371 67 229 599 (Latvia)

E-mail
info@virotherapy.eu